| Project/Area Number |
26430169
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中村 正樹 北里大学, 医療衛生学部, 助教 (30724554)
片桐 真人 北里大学, 医療衛生学部, 教授 (50152674)
馬嶋 正隆 北里大学, 医学部, 教授 (70181641)
松本 和将 北里大学, 医学部, 講師 (70306603)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | インターロイキン24 / 抗腫瘍性サイトカイン / IL-24 / 細胞治療 |
|---|
| Outline of Final Research Achievements |
In this study, antitumor effects such as cell proliferation inhibition, apoptosis induction and epithelial marker elevation, were significantly observed in retrovirally IL-24 introduced into prostate cancer defecting IL-24 receptors. Interestingly, those effects were not observed by administration of recombinant IL-24 to the prostate cancer cells. The detail of mechanism for the antitumor effects by introduced IL-24 may dissolve in the future.
|
